Amylyx’s ALS drug Relyvrio generates $71.4M in Q1

Submitted by admin on May 15, 2023 - 10:14am

Source:

Medical Marketing and Media

News Tags:

Headline:

snippet:

Amylyx co-CEO Justin Kleen announced that the company is launching a Phase 3 study of Relyvrio in progressive supranuclear palsy later this year.

Search form